SALUDyHERPES

Microblog de divulgación de ASAFHE, Asociación de Afectados por los virus del Herpes.

[SALUDyHERPES @SALUDyHERPES]

Aquí está el video sobre salud sexual! Editado durante el taller de ITS Help project 2021.
👉https://t.co/dZaevDIWy9

[Herpes Update @HerpesSupport_H]

3/ In mouse studies, removing or targeting gG significantly reduced the virus's ability to reach the nervous system. This suggests that blocking this protein could help prevent long-term infection.

[Herpes Update @HerpesSupport_H]

A growing global petition is calling for faster development of IM-250 (Adibelivir), a next-generation HSV treatment designed to target the virus where it hides in nerve cells. Supporters argue it could reduce outbreaks, viral shedding, and transmission far beyond current antivirals. With Phase 2 development now underway, thousands are urging regulators and stakeholders to prioritize progress for the billions affected by HSV. #IM250 #Adibelivir #CureResearch
https://t.co/r4Ac7NgSWE

[SALUDyHERPES @SALUDyHERPES]

https://t.co/E3hhJj0CkW

[Herpes Update @HerpesSupport_H]

New HSV vaccine research: Scientists developed three mRNA vaccine candidates and found that the bivalent gD2-gE1 vaccine produced the strongest protection in mice against genital herpes challenge.

The vaccine triggered robust antibody and T-cell responses, with its effectiveness linked to a stronger Type I interferon (IFN-I) response that boosted adaptive immunity.

While still preclinical, the findings offer valuable insights for the next generation of HSV vaccines. #Herpes #Vaccines #mRNA

[Herpes Update @HerpesSupport_H]

Bernard Roizman, one of the most influential HSV researchers in history, has passed away at age 96.

Roizman helped map the herpes simplex virus genome, uncover how HSV infects cells, identify key viral genes, and lay the foundation for modern antiviral, vaccine, gene therapy, and oncolytic virus research. His work transformed virology and continues to shape the search for better HSV treatments and a cure.

Rest in peace, Dr. Roizman. Your legacy will live on through generations of scientists and patients.

[Herpes Update @HerpesSupport_H]

A org petition urging faster development of IM-250 (Adibelivir) has surpassed 4,000 signatures. Supporters say this next-generation HSV antiviral could reduce viral shedding, transmission, and recurrences by targeting the virus more effectively than current treatments. Meanwhile, IM-250 has already completed Phase 1 and advanced to Phase 2 clinical development.
https://t.co/WxsBgnAk1g

[Herpes Update @HerpesSupport_H]

Theralase ($TLT / $TLTFF) continues expanding its pipeline in 2026, with recent updates highlighting new findings on how Ruvidar® inactivates HSV-1, ongoing bladder cancer studies, and multiple financings totaling over C$7.5M to support development. The company says it plans to advance regulatory submissions for Ruvidar® and begin GLP toxicology studies for Rutherrin®. 📈 #HSV #Biotech #Theralase
https://t.co/O3f0qymj5I

[Herpes Update @HerpesSupport_H]

🧵1/7
🚨 HSV Clinical Trial Update: IM-250
A new Phase 1b/2a clinical trial is evaluating IM-250, a next-generation oral helicase-primase inhibitor, as a suppressive treatment for recurrent genital HSV-2 infection.
#HSV #Herpes

[Dr. Pablo Barrecheguren 🧠 @pjbarrecheguren]

Cuando investigaba pensaba que bastaba con trabajar para descubrir algo que mejorara la vida de las personas. Ahora sé que no es suficiente, que como científico he de tener también una postura y activismo político si de verdad quiero que los avances lleguen a toda la gente.

[Herpes Update @HerpesSupport_H]

A new case report highlights how HSV can sometimes affect more than the skin and nerves. Researchers described herpes simplex virus esophagitis in an immunocompetent patient, where diagnosis was challenging because symptoms mimicked other gastrointestinal conditions. After proper testing identified HSV, antiviral treatment led to successful recovery. The case is another reminder that herpes viruses can occasionally cause serious internal complications even in people without known immune deficiencies.
https://t.co/MApy7QyhC8

[Herpes Update @HerpesSupport_H]

Right now, pritelivir is being reviewed specifically for immunocompromised patients with refractory/resistant HSV infections. That’s the population studied in the Phase 3 trial and the indication submitted to the FDA.

So if it gets approved at the end of 2026, the first approval will most likely only be for immunocompromised people not the general HSV population.

That said, pritelivir has already shown antiviral activity in immunocompetent patients in earlier studies, including reductions in viral shedding and lesions.

Many people hope that if the launch goes well and safety data continue looking good, the company could later pursue broader approvals for recurrent HSV in immunocompetent individuals. But as of now, there’s no official FDA filing for “everyone” yet.

[SALUDyHERPES @SALUDyHERPES]

Tal cual...

[Herpes Update @HerpesSupport_H]

A newly reported medical case highlights how HSV-1 can sometimes cause severe gastrointestinal disease even in healthy people without immune system problems. Doctors described an immunocompetent man who developed HSV-1 enteritis, an extremely rare complication where the virus inflames the intestines instead of causing the typical oral or genital sores.

The case reminds clinicians that herpes simplex virus is not always limited to the skin or mucosal surfaces. In rare situations, HSV-1 can spread internally and affect organs such as the esophagus, liver, or intestines, potentially leading to serious illness if diagnosis is delayed. Similar rare reports of HSV-related gastrointestinal disease in immunocompetent patients have appeared in medical literature over the years.

Physicians emphasized that early antiviral treatment remains critical. Prompt recognition and treatment with antivirals like acyclovir can significantly improve outcomes and prevent complications.

The report also underscores how much remains unknown about HSV behavior in the body. While most HSV-1 infections are mild or asymptomatic, rare systemic cases continue to challenge assumptions about the virus and highlight the need for better awareness, diagnostics, and improved antiviral therapies.

Source:👉https://t.co/oeycicX3L1

[Herpes Update @HerpesSupport_H]

AiCuris VP Dr. Alexander Birkmann will discuss the future of HSV antiviral drug development on May 28, including progress on pritelivir and next-generation herpes treatments. With 20+ years in antiviral research, his work spans from early-stage science to late-stage clinical trials.
https://t.co/XPqeYWyNy0

[Herpes Update @HerpesSupport_H]

New research from https://t.co/ixQ8x3eOxh reveals that HSV-1 can actually “fluidize” the nucleus of human cells to replicate faster.
The virus uses a protein called ICP4 to loosen the dense structure inside the nucleus, creating more space for viral replication factories. Blocking this process reduced viral production by 4x in lab studies.
This discovery could open the door to new antiviral strategies targeting how HSV manipulates cells — not just the virus itself. 👀

[Herpes Update @HerpesSupport_H]

Pritelivir continues to show major promise for immunocompromised people with refractory HSV infections. In Phase 3 PRIOH-1 data, it significantly outperformed current standard treatments in lesion healing while also showing better safety and tolerability. FDA Priority Review is now underway, with a decision expected in Q4 2026. 👀
👇
https://t.co/wHm1HsmoQM

[Herpes Update @HerpesSupport_H]

🚨New Harvard research suggests certain gram-positive bacteria including Lactobacillus may naturally help suppress HSV-1 & HSV-2 infection.
Researchers found bacterial cell wall components reduced HSV infectivity in cells and improved outcomes in mice, highlighting the vaginal microbiome as a possible ally in future herpes prevention and treatment strategies.
https://t.co/HlT0035g7b

[Infosalus @infosalus_com]

Investigadores desarrollan un método pionero para evaluar materiales antivirales sin laboratorios de alta seguridad

https://t.co/GNgjK6U62V

[Herpes Update @HerpesSupport_H]

New research identified PR130, a regulatory subunit of PP2A, as a key host factor that helps HSV-1 replicate. Blocking this pathway significantly reduced viral replication, highlighting a potential new antiviral target beyond traditional HSV drugs. Another step toward smarter therapies against herpes.
👇
https://t.co/7Feakm95Fd

[Herpes Update @HerpesSupport_H]

🚨 Another HSV antiviral program enters the pipeline.
🇨🇳 Boyuan Pharmaceutical disclosed new herpes simplex virus (HSV) inhibitors that could potentially be used for both HSV infections and even dementia-related research. The details are still early/patent-stage, but it’s another sign that HSV drug development is accelerating globally.
More companies are now exploring next-generation antivirals beyond acyclovir.
👇👇
https://t.co/osRMJqSlhB

[SINC @agencia_sinc]

🧬 La herramienta Cas12a2 actúa como un ‘interruptor letal’ que tritura el ADN de células tumorales o infectadas sin afectar a las sanas. Podría abrir nuevas vías contra el cáncer y las infecciones virales.

Por @AnaHernandoDyO

https://t.co/IkMU4QTKaD